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Several members of the human tissue kallikrein-related peptidase (KLK) family are emerging cancer biomarkers. The aim of this study
was to analyse the expression of a panel of KLKs in colorectal cancer and to find out if the multiparametric combination of them can
increase the accuracy of prediction of patients survival beyond the traditional clinical information. Nine KLKs (KLK5-8, KLK10, KLK11,
KLK13-15) were measured using ELISA assays in cytosolic extracts of 122 colon cancer tissues and their nearby normal mucosa,
obtained during surgery. The mean levels of almost all KLKs in tumour tissues were significantly different from their counterparts of
normal tissue (Po0.0001). KLK 5, 6, 7, 13, 14 were significantly associated with overall survival in univariate analysis, but after adjusting
for age, TNM and differentiation stage, only KLK5 (HR: 1.24 (95% CI: 1.05–1.47)), KLK7 (HR: 1.57 (95% CI: 1.04–2.37)) and KLK14
(HR: 1.43 (95% CI: 1.05–1.94)) remained significant. Addition of a panel of selected KLK markers to clinical parameters gave an
increment in AUC of 0.86 beyond the clinical factors at year 1, showing that it can increase the accuracy of prediction of overall
survival beyond the traditional clinical information, particularly the short-term (1 year) survival after surgery.
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Colorectal cancer (CRC) is the cause of half a million deaths
worldwide every year. There are also about 1 million new cases
diagnosed annually, making it the third most common type of
cancer in the world, despite the fact that it mostly affects
populations of western lifestyle (American Cancer Society, 2005;
McCracken et al, 2007). The variation in cancer survival within the
same countries depends on the socio-economic level of the people
affected (Coleman et al, 2008). In the past few years, the death rate
caused by CRC has been reduced, mainly because of increased
screening based on serum markers, such as carcinoembryonic
antigen (Sturgeon, 2002), endoscopic technology and improved
treatment of the disease (Duffy et al, 2003). Tissue-based markers
have been proposed as possible prognostic markers and predictors
of response to treatment. Such markers include thymidilate
synthase, the transcription factor p53, the oncogene K-ras and
the adenomatous polyposis coli gene. Nevertheless, there are
remarkable contradictions in the literature with regard to the
relation between common CRC genes and prognosis (Anwar et al,
2004). Therefore, extensive research is needed to blend current
endoscopic and surgical technology with specific molecular
markers that will discriminate subgroups of patients for prognosis
or specific targeted therapies.
Proteases may represent good diagnostic/prognostic bio-
markers, as they are involved in cancer progression (Duffy,
1996). Human tissue kallikrein-related peptidases (KLKs) are a
family of 15 serine proteases with diverse physiological functions.
KLKs play important roles in different physiologic processes such
as regulation of cell growth and differentiation, tissue remodelling,
angiogenesis (Borgono and Diamandis, 2004), skin desquamation,
human semen liquefaction (Pampalakis and Sotiropoulou, 2007),
dental enamel formation (Lu et al, 2008), neuro-degeneration
(Scarisbrick et al, 2008), inflammation (Oikonomopoulou et al,
2007), cervico-vaginal physiology (Shaw and Diamandis, 2008),
and vascularisation (Smith et al, 2008). So far, KLKs have been
widely examined as cancer biomarkers, mostly in steroid-
hormone-regulated cancers (Emami and Diamandis, 2007),
because steroid hormones play an important role in the regulation
of kallikrein transcription (Paliouras et al, 2007). Many members
of the kallikrein family have been reported to be promising
diagnostic/prognostic biomarkers for several cancer types, includ-
ing breast, ovarian, prostate and testicular carcinomas (Borgono
and Diamandis, 2004). However, recent studies indicate that other
mechanisms probably cooperate in KLK regulation, including the
use of alternative promoters (Christophi et al, 2004), the
production of multiple splice variants (Pampalakis et al, 2006)
or epigenetic alterations, like DNA methylation and histone
modification (Pampalakis et al, 2004; Emami and Diamandis,
2007). Kallikrein-related peptidases may also be involved in cancer
pathogenesis by degrading extracellular matrix proteins or
promoting angiogenesis (Borgono and Diamandis, 2004). Few
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far concerning lung (Petraki et al, 2006; Planque et al, 2008),
pancreatic (Yousef et al, 2004; Dong et al, 2008), head and
neck (Chung et al, 2004) and brain (Prezas et al, 2006b) cancers
and leukaemia (Roman-Gomez et al, 2004) and their relation
with KLKs. Until now, only KLK6 and KLK10 have been
examined as biomarkers in CRC by Ogawa et al (2005) and
Feng et al (2006) using real time PCR and by Yousef et al (2004)
using in silico analysis. The aim of this study was to evaluate
whether human tissue KLKs, alone or in combination with
established clinical and pathological variables in a multiparametric
model, can be used as potential prognostic markers for CRC
patients.
MATERIALS AND METHODS
Clinical samples
Primary colorectal cancer specimens from 122 patients, collected
at the Oncologic Hospital of Athens ‘Saint Savvas’, were
staged according to Dukes’ operative staging system. Paired
normal colon mucosa, sufficiently separated from the tumours,
was available for all cancer samples. Both cancer and normal
samples were histologically confirmed by eosin–haematoxylin
staining. Investigations were carried out in accordance with
the ethical standards of the Helsinki Declaration of 1975, as
revised in 1983. Histologic diagnoses and grading of tumours
were made based on the revised World Health Organization
(WHO) classification for colon tumours. All cases under study
came from complete surgical excision of the tumour. No
chemotherapy or radiotherapy was administered before surgery.
Clinical and pathological characteristics such as age, tumour
size, TNM stage, tumour grade and differentiation, were available
for all patients. Two time-to-event outcomes after surgery were
recorded: Disease-Free Survival (DFS) and Overall Survival (OS).
DFS in each case was defined as the time interval between the
date of surgical removal of the primary cancer and the date of
the first documented evidence of relapse. OS was defined as the
time interval between the date of surgery and the date of death, or
the date of last follow up for those who were alive at the end of
the study.
Ethics
Agreement of the Institute’s Ethics Committee for the scientific
analysis of tumour tissues, as well as patients’ written informed
consent had been obtained.
Preparation of colon tissue extracts
Upon collection, colon tissues were snap frozen in liquid nitrogen
and subsequently transferred to  801C until extraction. Frozen
samples (0.2g) were pulverised using a Mikro-Dismembrator – U
(Sartorius, Goettingen, Germany) and processed as described
earlier (Shaw and Diamandis, 2007). Protein concentration of the
extracts was determined (Pierce Chemical Co, Rockford, IL, USA).
Immunofluorometric ELISA measurement of kallikreins in
colorectal cytosolic extracts
Concentration of KLKs was measured with a non-competitive
immunoassay, described earlier (Shaw and Diamandis, 2007;
Planque et al, 2008). Two types of configurations of ELISA were
used in this study, using either monoclonal–monoclonal (KLK5,
KLK6, KLK7, KLK8, KLK10, KLK13) or monoclonal–polyclonal
(KLK11, KLK12, KLK14) combinations. All ELISAs were tested
negative for cross-reactivity against other KLKs.
Statistical methods
Marker measurements were logarithmically transformed due to
skewness in the distributions. The differentiation in marker
expression in paired tumour and normal tissues was evaluated
by the paired t-test on the transformed values. The relationships
between biomarkers and tumour and patient characteristics
were examined with the Kruskal–Wallis test. Spearman’s rank
correlation coefficient was used to assess the correlations among
biomarkers (Supplementary Table S1 along with hierarchical
clustering based on Spearman’s correlation). Cox regression model
was applied to evaluate the hazard ratios (HR) of biomarkers on
DFS or OS applying univariate or multivariate analyses. Clinical
variables, including age, tumour size, TNM stage, grade and
tumour differentiation were adjusted in multivariate Cox propor-
tional hazards models. Both HRs and 95% confidence interval
(95% CI) were calculated on log-transformed biomarkers and
were represented with two-sided P-values. In this study, to further
evaluate the prognostic usefulness of the markers, we used a
receiver operating characteristic (ROC) curve (Heagerty et al,
2000). ROC analysis was first conducted on individual markers
and then on their combination to explore the possibility of a
marker panel to lead to improved performance. We used an
algorithm that gives a single composite score in the sense that
the ROC curve is maximised at every threshold value. To get
a prognostic index we built marker panels at year 1 and 5 after the
surgery using a weighted logistic regression that is appropriate
for censored failure time (Zheng et al, 2006) with the stepwise
selection. The predictive accuracy of composite scores was
evaluated based on a re-sampling algorithm to correct for potential
overfitting when deriving the combinatory rule (Supplementary
Figure S1). Specifically, we randomly split data into a training
set and a validation set. The training set included two thirds of the
observations, and the validation set included one third of the
observations. Using the training set, we first operated a model
selection from which the final selected model gave rise to the
linear combination rule. We then, calculated two ROC curves for
the linear score: one with using data from the training set and
the other using the validation set. The vertical differences
between the two ROC curves gave the overestimation of the
sensitivities at a given specification. The whole procedure was
repeated 100 times, and these differences were averaged to yield an
estimate of the expected overestimation. We present both the
original ROC curves and the ROC curves that are corrected for
overestimation. All analyses were done using Statistical Analysis
System (SAS Institute Inc., Cary, NC, USA) and S-plus 7.0 software
(Insightful Corp., Palo Alto, CA, USA).
RESULTS
Distribution of kallikreins between colon cancer and its
paired normal tissues
To determine the clinical utility of the kallikrein family as potential
tumour markers for colorectal cancer, the expression profile of
several members of the family was examined by immuno-
fluorometric ELISA assays, previously developed and validated
(Dorn et al, 2007; Shaw and Diamandis, 2007; Planque et al, 2008).
The detection limit was 0.05mgl
 1 for KLK5, KLK6, KLK10,
KLK13, KLK14 and KLK15, but only 0.2mgl
 1 for KLK7, KLK8
and KLK11. Table 1 shows the distribution of numerical variables
of the study. The differential expression of KLK5-8, KLK10, KLK11
and KLK13-15 was evaluated by the paired t-test on log-
transformed values. As shown in Table 2, the means of kallikrein
concentrations between cancer and normal samples were sig-
nificantly different for all KLKs (Po0.001), with the exception of
KLK5 (P¼0.92) and KLK14 (P¼0.87).
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colon cancer patients
Cox regression models were used to examine the association
between OS and kallikreins, and clinical and pathological
parameters (Table 3). In univariate analysis the clinical and
pathological parameters, age, grade, TNM stage and tumour
differentiation, are significantly associated with OS (P¼0.001,
P¼0.014, Po0.001 and P¼0.004, respectively), whereas in
multivariate analysis only age, TNM stage and tumour differentia-
tion remained significant (P¼0.005, P¼0.004 and P¼0.036,
respectively). Kallikrein markers KLK5, KLK6, KLK7, KLK13,
and KLK14 were significantly associated with OS (Pp0.05) in
univariate analysis, but after adjusting for the significant clinical
factors, age, TNM stage and differentiation, only KLK5 (HR: 1.24
(95% CI: 1.05–1.47)), KLK7 (HR: 1.57 (95% CI: 1.04–2.37)) and
KLK14 (HR: 1.43 (95% CI: 1.05–1.94)) remained significant
(Table 3). Whereas, when using the forward selection with a
P-value of 0.1 as entry criterion in the Cox regression, only KLK14
and KLK7 were selected in the multi-marker model. The fitted
Cox model is: 0.054 Ageþ1.629 TNM (Stage III/IV)þ0.703 
Differentiation (poor)þ0.300 logKLK14þ0.364 logKLK7.
The clinical usefulness of kallikreins for prediction of OS status
at 1 year and 5 years after operation for CRC was evaluated by ROC
curve analysis. For OS, age and TNM stage alone were very
predictive with an area under the curve (AUC) of 0.79 at both year
1 and year 5 under the time-dependent ROC curve. However, the
addition of a panel of selected KLK markers (KLK14) at year 1 by
stepwise selection in weighted logistic regression, gave an
increment in AUC from 0.79 to 0.86, but much less at year 5
(Figure 1).
Association of kallikrein markers with disease-free
survival of colon cancer patients
Cox regression model results for colorectal cancer DFS are listed in
Table 4. Among all clinical and pathological parameters, only TNM
stage had a significant (P¼0.04) hazard ratio in multivariate
analysis. Kallikrein markers KLK5, KLK6, KLK7, KLK10, KLK13,
and KLK14 were significantly associated with DFS (Pp0.05) in
univariate analysis, but after adjusting for TNM stage only KLK14
(HR: 1.33 (95% CI: 1.05–1.68)) remained significant and no other
marker entered into the multivariate Cox model using the forward
selection with a P-value of 0.1 as entry criterion. The fitted Cox
model is: 1.404 TNM (Stage III/IV)þ0.283 logKLK14. The
clinical usefulness of kallikreins for the prediction of DFS status at
1 year and 5 years after operation for colorectal cancer was also
evaluated by ROC curve analysis. The addition of a panel of
selected KLK markers by stepwise selection in weighted logistic
regression hardly gave any increment values at both year 1 and
year 5 (Figure 2).
DISCUSSION
Tissue or serum levels of KLKs have been examined either
individually or in panels as diagnostic or prognostic factors in
different types of cancer (Borgono and Diamandis, 2004; Dorn
et al, 2007; Paliouras et al, 2007; Zheng et al, 2007; Planque et al,
2008). With the development of technology and automation and
the promising concept of individualised therapy, it is tempting to
examine concurrently, in panels, many different parameters as
cancer biomarkers. In this study, we analysed the cytosolic extracts
of 122 pairs of cancer/normal colon mucosa for the expression of
nine KLKs on the protein level, to evaluate the clinical utility of
this gene family as prognostic markers for colorectal cancer. Using
a sensitive and specific immunofluorometric assay developed at
Professor Diamandis’s laboratory (University of Toronto, Ontario,
Canada), we studied the alterations in the expression between
cancer and paired normal colorectal tissue for nine KLKs. In
addition, we used extensive statistical analysis to examine whether
Table 2 Marker distribution in 122 paired tumour (1) and normal tissues (0) and the distribution of the expression ratios of tumour to normal
Marker CA/normal Median (1st, 3rd quartile) Mean ratio
a (s.e.) 95% CI P-value**
KLK5 1 0.005 (0.004, 0.008) 0.985 (0.146) 0.736–1.318 0.9198
0 0.006 (0.005, 0.01) .
KLK6 1 0.4485 (0.104, 1.684) 15.548 (2.47) 11.388–21.228 o0.0001
0 0.0315 (0.01, 0.06) .
KLK7 1 0.29 (0.171, 0.51) 2.323 (0.235) 1.905–2.832 o0.0001
0 0.13 (0.078, 0.217) .
KLK8 1 0.009 (0.005, 0.023) 2.001 (0.221) 1.611–2.485 o0.0001
0 0.0055 (0.004, 0.008) .
KLK10 1 0.464 (0.071, 2.206) 33.307 (6.398) 22.857–48.535 o0.0001
0 0.008 (0.005, 0.029) .
KLK11 1 0.817 (0.291, 1.98) 3.131 (0.435) 2.385–4.11 o0.0001
0 0.266 (0.15, 0.568) .
KLK13 1 0.009 (0.005, 0.016) 1.518 (0.148) 1.254–1.838 o0.0001
0 0.005 (0.004, 0.008) .
KLK14 1 0.035 (0.019, 0.061) 0.98 (0.123) 0.767–1.253 0.8738
0 0.043 (0.032, 0.064) .
KLK15 1 0.132 (0.063, 0.256) 3.263 (0.512) 2.4–4.438 o0.0001
0 0.0365 (0.006, 0.14) .
CI¼confidence interval; KLK¼kallikrein-related peptidase.
aBack-transformed mean log ratios of cancer to normal expressions. **P-values from the paired t-test on
log-transformed values.
Table 1 Distribution of numerical variables of the study
Quartiles
25 50 75
Variable Mean±s.e. Range (median)
Patient age (years) 68.7±0.8 31.0–91.0 61.7 70.0 76.0
Tumour size (cm) 4.7±0.1 0.2–12.0 3.5 4.5 5.5
Follow-up (months; n¼122) 37.2±2.5 1.0–132.0 10.0 35.5 54.7
DFS (months; n¼122) 31.3±2.7 0.0–132.0 4.2 24.0 54.0
OS (months; n¼122) 37.1±2.5 1.0–132.0 10.0 35.5 54.7
DFS¼disease-free survival; OS¼overall survival.
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sthe use of those KLKs, as a panel, has to offer more information to
the prognosis of colorectal cancer patients than the already
existent clinical and pathological parameters.
Almost all KLKs, except KLKs 5 and 14, effectively separate
cancer from paired normal tissue in a statistically significant
manner. This is in agreement with our unpublished data showing
overexpression of several kallikreins (KLK6, KLK7, KLK10) on the
mRNA level of cancer samples as compared with their paired
normal colon mucosa. Similar studies using the same method with
us and examining the expression patterns of several kallikreins
either in ovarian cytosolic extracts (Dorn et al, 2007; Zheng et al,
2007) or serum samples from lung cancer patients (Planque et al,
2008), have revealed unique patterns.
The present report confirms the in silico study by Yousef et al,
2004, showing an overexpression of KLK6, KLK8 and KLK10 in
CRC. It is also in agreement with Ogawa et al (2005), reporting that
KLK6 mRNA overexpression in CRC correlates with poor prognosis
of CRC patients. Furthermore, we are in line with Feng et al
(2006), reporting upregulation of KLK10 in CRC. We underline as
important the difference noticed between the upregulation of
KLK10 in CRC shown in this work and its downregulation shown
in previous studies and attributing it to CpG island hypermethyla-
tion, examining other cancer tissue types, like breast, prostate or
ovarian (Sidiropoulos et al, 2005), gastric (Huang et al, 2007), head
and neck (Worsham et al, 2006), testicular (Luo et al, 2001) and
lung (Planque et al, 2008). However, contradictory results have
Table 3 The univariate and multivariate Cox regression analysis for the overall survival
Univariate Multivariate
Clinical variable N (%) HR CI P*H R C I P-value**
Age (years) 123 1.06 (1.02, 1.09) 0.001 1.07 (1.02, 1.12) 0.004
Tumour size 116 1.01 (0.84, 1.22) 0.911 1.07 (0.73, 1.56) 0.721
Grade
I or II 65 (68) 1 1
III or IV 30 (32) 2.4 (1.19, 4.82) 0.014 0.57 (0.17, 1.88) 0.356
TNM stage
I or II 59 (51) 1 1
III or IV 56 (49) 4.39 (2.08, 9.26) o0.001 4.71 (1.62, 13.66) 0.004
Differentiation
Well-moderate 99 (86) 1 1
Poor 16 (14) 2.92 (1.41, 6.02) 0.004 3.7 (1.09, 12.6) 0.036
Markers
KLK5 126 1.25 (1.1, 1.42) 0.001 1.24 (1.05, 1.47) 0.012
KLK6 127 1.26 (1.03, 1.54) 0.026 1.09 (0.85, 1.39) 0.493
KLK7 127 1.78 (1.32, 2.4) o0.001 1.57 (1.04, 2.37) 0.032
KLK8 127 1.1 (0.91, 1.34) 0.335 1.01 (0.78, 1.32) 0.914
KLK10 127 1.15 (1, 1.33) 0.051 1.12 (0.94, 1.34) 0.193
KLK11 126 1.2 (0.99, 1.46) 0.057 1.16 (0.91, 1.49) 0.236
KLK13 127 1.31 (1.03, 1.68) 0.028 1.36 (1, 1.87) 0.053
KLK14 127 1.32 (1.1, 1.6) 0.003 1.43 (1.05, 1.94) 0.022
KLK15 127 1.01 (0.78, 1.32) 0.934 1.02 (0.77, 1.36) 0.891
CI¼confidence interval; KLK¼kallikrein-related peptidase. *P-values from univariate Cox regression. **P-values for clinical variables are from multivairate Cox regression after
adjusting for each other. P-values for markers are from multiviariate Cox regression with significant clinical variables from above and the marker of interest.
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Figure 1 ROC curves for 1- and 5-year overall survival for ‘Clinical’: age and TNM stage; and ‘ClinicalþMarkers’: age, TNM stage, and selected marker
panels of KLK(s). The marker panel at year 1 is: KLK14. The marker panel at year 5 is: KLK8, KLK10, KLK14, and KLK15.
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in cancers, as breast (Luo et al, 2002), ovarian (Luo et al, 2003),
gastric (Feng et al, 2006) and head and neck (Dasgupta et al, 2006).
All members of the KLK family have been examined as
biomarkers for different types of cancer and reviewed recently
by Paliouras et al, 2007. Current results showing an overexpression
of KLK6 in CRC may be explained by the fact that KLK6 acts as a
mediator of K-Ras-dependent migration of CRC cells, as reported
by Henkhaus et al (2008a) and that K-RAS mutations are common
in CRC, occurring in approximately 50% of cases. We have
recently demonstrated that ovarian cancer cells of epithelial origin
like colon cells, stably transfected to express KLKs 4, 5, 6 and 7
were significantly more invasive in vitro and formed larger
tumours in mice (Prezas et al, 2006a). Furthermore, Klucky et al,
2007 trying to explain the function of KLK6 in cancer, provided
evidence that KLK6 induces E-cadherin shedding and thus,
promotes cell proliferation, migration, and invasion. In addition,
recent data presented by Henkhaus et al (2008b) indicate a central
role for caveolin-1, the main structural protein of caveolae in both
KLK6 gene expression and protein secretion of colon cancer cell
line HCT116.
Cytosolic KLK7 protein in this study and KLK7 transcripts from
the same samples used in an earlier study conducted in our lab
(Talieri et al, 2009), seem to follow the same pattern of
upregulation. As reported recently by Ramani and Haun (2008),
overexpression of KLK7 in tumour cells may play an important
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Figure 2 ROC curves for 1- and 5-year disease-free survival for ‘Clinical’: age and TNM stage; and ‘ClinicalþMarkers’: age, TNM stage, and selected
marker panels of KLK(s). The marker panel at year 1 is: KLK10 and KLK14. The marker panel at year 5 is: KLK5, KLK6, KLK8, KLK10, KLK13, KLK14,
and KLK15.
Table 4 The univariate and multivariate Cox regression analysis for the disease-free survival
Univariate Multivariate
Clinical variable N (%) HR CI P*H R C I P-value**
Age (years) 124 1.04 (1.01, 1.07) 0.013 1.03 (0.99, 1.08) 0.101
Tumour size 116 1.01 (0.84, 1.21) 0.951 0.94 (0.68, 1.31) 0.721
Grade
I or II 65 (68)
III or IV 31 (32) 3.04 (1.55, 5.97) 0.001 1.33 (0.45, 3.95) 0.605
TNM stage
I or II 59 (51)
III or IV 57 (49) 4.1 (2.01, 8.39) 0.000 2.86 (1.05, 7.79) 0.040
Differentiation
Well-moderate 99 (85)
Poor 17 (15) 2.78 (1.42, 5.43) 0.003 2.04 (0.72, 5.81) 0.182
Markers
KLK5 127 1.21 (1.07, 1.37) 0.002 1.16 (0.99, 1.37) 0.065
KLK6 128 1.23 (1.03, 1.48) 0.024 1.09 (0.9, 1.33) 0.384
KLK7 128 1.47 (1.14, 1.9) 0.003 1.28 (0.96, 1.72) 0.095
KLK8 128 1.09 (0.91, 1.31) 0.349 1 (0.8, 1.26) 0.972
KLK10 128 1.15 (1.01, 1.31) 0.040 1.07 (0.92, 1.23) 0.387
KLK11 127 1.18 (0.99, 1.41) 0.068 1.12 (0.9, 1.39) 0.298
KLK13 128 1.32 (1.04, 1.67) 0.025 1.29 (0.98, 1.71) 0.074
KLK14 128 1.28 (1.06, 1.54) 0.011 1.33 (1.05, 1.68) 0.018
KLK15 128 1.07 (0.84, 1.37) 0.584 1.12 (0.85, 1.46) 0.425
CI¼confidence interval; KLK¼kallikrein-related peptidase. *P-values from univariate Cox regression. **P-values for clinical variables are from multivairate Cox regression after
adjusting for each other. P-values for markers are from multiviariate Cox regression with clinical variable TNM stage and the marker of interest.
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components, such as fibronectin. Our lab has shown in the past
that KLK7 may serve as a potential biomarker for breast cancer
patients (Talieri et al, 2004) and that its overexpression in
intracranial tumours reveals a less favourable outcome (Prezas
et al, 2006b). Moreover, we have shown that U-251-MG
glioblastoma cells transfected with KLK7 showed increased
invasive potential in an in vitro Matrigel assay (Prezas et al,
2006b). Present work shows upregulation of KLK8, although it is
not associated either with OS or DFS. This is in line with our
previous work (Prezas et al, 2006b) in brain cancer, where we did
not find any association of KLK8 with DFS or OS. In addition, in
the same study, glioblastoma U-251-MG cells stably transfected
by the KLK8 gene did not show invasion in the Matrigel assay.
Although the expression of KLK14 of CRC samples does not seam
to be significantly different from their normal counterparts, it is
the marker that remained statistically significant in association
with the survival outcomes: DFS and OS in the Cox regression
univariate and multivariate analysis showing unfavourable prog-
nosis for the patients. KLK14 is involved in extracellular matrix
degradation (Borgono et al, 2007) and the present finding may be
associated with response to treatment.
As most members of the KLK family display differential
expression in CRC, it is very tempting to speculate on their
potential role in CRC initiation and progression. Studies on the
physiological function of KLKs in normal colon will shed more
light into the roles of these enzymes in colon cancer and other
diseases of colon and rectum. In addition, these enzymes may
represent promising future therapeutic targets.
We need to point out that even though a combination of selected
clinical factors and KLKs panel showed an increase in OS predic-
tion at 1 year after the surgery with AUC of 0.86 under the time-
dependent ROC curve, after correction for possible overfitting
from the model selection process estimated by cross-validation,
the corrected AUC was only at 0.69 and it was no better than the
prediction of age and TNM stage alone (Supplementary Figure S1).
Therefore, the performance of this selected KLK marker panel and
the combination rule defined in this particular data need to be
further evaluated in an independent validation study.
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